printemailclick to share buttonfacebooktwitterlinkedin
OSCCD Cancer Drug Reviews
 

The Ontario  Steering Committee for Cancer Drugs (OSCCD) reviews select cancer drugs for public funding in Ontario. The Executive Officer, Ontario Public Drug Programs, seeks the committee’s advice in making final funding decisions. Drug-specific summaries outlining the committee’s recommendations and reasons are available below.

Please note, cancer drugs reviewed by the pan-Canadian Oncology Drug Review, are not subsequently assessed by this committee.

OSCCD Cancer Drug Review Summaries

To view a summary, click on the pdf icon.

Drug Name Indication OSCCD Review Date Funding Status Review Summary
aprepitant (Emend®) Chemotherapy-Induced Nausea and Vomiting Nov. 25, 2013 Approved Antiemetics Summary (PDF)
granisetron (Kytril®) Chemotherapy-Induced Nausea and Vomiting Nov. 25, 2013 Approved Antiemetics Summary (PDF)
ondansetron (Zofran®) Chemotherapy-Induced Nausea and Vomiting Nov. 25, 2013 Approved Antiemetics Summary (PDF)
Bevacizumab* (Avastin®) Recurrent Giloblastoma Multiforme Dec. 12, 2013 Denied See the Ministry ‘s website: EO Decisions and CED Recommendations

*The Ministry’s Committee to Evaluate Drugs, led this review with input from the OSCCD.

For current eligibility criteria for publicly funded cancer drugs, please visit the program-specific website:

Last modified: Wed, Jun 17, 2015
cancer care ontario | action cancer ontario   620 University Avenue Toronto Ontario, Canada M5G 2L7   Phone: 416.971.9800 Fax: 416.971.6888

Please help improve the quality of our website by answering 10 brief questions in our online survey. Would you like to participate?

YesNo